Doug Drysdale
| Doug Drysdale | |
|---|---|
| Born | 8 December 1969 |
| 🏳️ Nationality | British, American |
| 🎓 Alma mater | University of East Anglia |
| 💼 Occupation | Healthcare executive and Entrepreneur |
| 👔 Employer | Cybin Inc |
| Known for | Biopharmaceutic |
| Notable work | Former CEO at Alvogen and Pernix Therapeutics |
| Title | CEO at Cybin Inc |
Doug Drysdale, born on 8 December 1969, is a British-American pharmaceutics executive and entrepreneur. Since 2020, he has served as CEO of Cybin Inc., a Canadian biopharmaceutical company focused on developing psychedelic therapeutics for mental health disorders.[1] Previously, he was the CEO of Tedor Pharma, a U.S.-based contract development and manufacturing organization, from 2017 to 2020.[2]
Drysdale holds a bachelor's degree in Microbial and Molecular Biology from the University of East Anglia. He began his career in 1992 at DuPont Merck Pharmaceutical Company and later held key roles at Elan Corp and Actavis, serving as Vice President of Mergers and Acquisitions from 2004 to 2008.[3]
Career
Drysdale's career includes founding and leading Alvogen, expanding it to 35 countries within five years, and serving as chairman and CEO of Pernix Therapeutics from 2014 to 2016.[4][5] Under his leadership, Cybin Inc. achieved major milestones, including receiving FDA Breakthrough Therapy Designation for CYB003, a deuterated psilocybin analog for treating major depressive disorder (MDD).[6]
Recognitions
- 2011: Pharmaceutical Executive Distinguished Honor for the 2011 International Business Award.[7]
- 2012: Ernst & Young Entrepreneur of the Year Award for the New Jersey region.[8]
References
- ↑ "Cybin Corp Announces Doug Drysdale as Chief Executive Officer". 2020-09-01.
- ↑ "Tedor Pharma Makes Organizational Changes". Contract Pharma. Retrieved 2024-11-25.
- ↑ Hasse, Javier. "Former Actavis Head Of M&A Joins Psychedelics Company As CEO". Forbes. Retrieved 2024-11-22.
- ↑ "Houston pharmaceutical company restructures". www.bizjournals.com. Retrieved 2024-11-25.
- ↑ "New Pernix CEO's focus will be on expanding team". www.bizjournals.com. Retrieved 2024-11-25.
- ↑ O'Brien, Jack (2024-03-27). "Cybin CEO on FDA breakthrough designation for psychedelic drug treating MDD". MM+M - Medical Marketing and Media. Retrieved 2024-11-22.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs named:4 - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs named:5
This article "Doug Drysdale" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Doug Drysdale. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
